Search

VX-702

In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA. … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor.

Lumiracoxib

On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID).

Pentastarch

It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. … When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.

Daledalin

Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. … It was in trials for depression in the 1970s but never marketed.

Ebola Zaire vaccine (live, attenuated)

[L10866] In 2014, Merck Inc. signed a licensing agreement with NewLink for further development and marketing. … [L10854] By introducing the relatively inactive viral protein to the patient, the patient’s immune system learns to recognize and attack the virus if he or she is exposed to it in the future.

Lemborexant

[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Calcium phosphate dihydrate

Alclofenac

Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.

mRNA-1283

[L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … 2 spike protein, allowing for a more targeted immune response and the use of a significantly smaller amount of mRNA per dose.

Bendroflumethiazide

A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders.